MedTrace Logo

Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer

NCT00392769 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2012-09-06

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to learn if cetuximab can help to control the disease in patients who have recurrent endometrial cancer.

Primary Objective:

1\. To determine the overall disease control rate of cetuximab in patients with progressive or recurrent endometrial cancer.

Secondary Objectives:

1. To determine the duration of disease control, time to disease progression, and survival of this cohort of patients.
2. To determine the nature and degree of toxicity of cetuximab in this cohort of patients.
3. To correlate biologic markers with response to therapy if tissue is available.

Conditions

Interventions

DRUG

Cetuximab

Initial Dose = 400 mg/m\^2 IV Over 120 Minutes, Followed by Weekly Infusions at 250 mg/m\^2 IV Over 60 Minutes.

Sponsors & Collaborators

Principal Investigators

  • Judith Wolf, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00392769 on ClinicalTrials.gov